Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RAYZ 8009

Next Previous
X
Search
Drug Profile

RAYZ 8009

Alternative Names: Glypican-3 targeted radiotherapy - RayzeBio; GPC3 targeted radiotherapy - RayzeBio; RAYZ-8009

Latest Information Update: 28 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PeptiDream; RayzeBio
  • Developer RayzeBio
  • Class Antineoplastics; Drug conjugates; Macrocyclic compounds; Peptides; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Liver cancer

Most Recent Events

  • 26 Feb 2024 RayzeBio has been acquired by Bristol-Myers Squibb
  • 02 Jun 2023 Pharmacodynamics data from preclinical trials in Liver cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 31 Mar 2023 Preclinical trials in Liver cancer (Diagnosis) in USA (unspecified route) (RayzeBio website, March 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top